More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

The Cyprus pulmonology society on Thursday urged Health Minister Michael Damianos to approve a respiratory syncytial virus ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...